NEUROGENE INC (NGNE) Stock Price & Overview
NASDAQ:NGNE • US64135M1053
Current stock price
The current stock price of NGNE is 19.3 USD. Today NGNE is down by -5.16%. In the past month the price decreased by -6.94%. In the past year, price increased by 119.57%.
NGNE Key Statistics
- Market Cap
- 298.957M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -4.24
- Dividend Yield
- N/A
NGNE Stock Performance
NGNE Stock Chart
NGNE Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to NGNE. When comparing the yearly performance of all stocks, NGNE is one of the better performing stocks in the market, outperforming 92.35% of all stocks.
NGNE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NGNE. NGNE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
NGNE Earnings
NGNE Forecast & Estimates
14 analysts have analysed NGNE and the average price target is 82.62 USD. This implies a price increase of 328.08% is expected in the next year compared to the current price of 19.3.
NGNE Groups
Sector & Classification
NGNE Financial Highlights
Over the last trailing twelve months NGNE reported a non-GAAP Earnings per Share(EPS) of -4.24. The EPS increased by 1.01% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -31.31% | ||
| ROE | -34.11% | ||
| Debt/Equity | 0 |
NGNE Ownership
NGNE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.36 | 370.255B | ||
| AMGN | AMGEN INC | 15.29 | 188.011B | ||
| GILD | GILEAD SCIENCES INC | 15.42 | 166.661B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.86 | 110.013B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.03 | 77.991B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.36 | 42.088B | ||
| INSM | INSMED INC | N/A | 31.319B | ||
| BIIB | BIOGEN INC | 11.67 | 26.98B | ||
| NTRA | NATERA INC | N/A | 25.887B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.7 | 22.916B | ||
| MRNA | MODERNA INC | N/A | 19.573B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.333B | ||
| INCY | INCYTE CORP | 11.79 | 17.971B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NGNE
Company Profile
Neurogene, Inc. is a clinical-stage biotechnology company, which engages in the development of product portfolio of genetic medicines for rare neurological diseases. The company is headquartered in New York City, New York and currently employs 107 full-time employees. The company went IPO on 2014-03-07. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is in development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. NGN-401 is being evaluated in female patients with Rett syndrome in a Phase 1/2 open-label, multi-center clinical trial that assesses the safety, tolerability, and efficacy of two doses of NGN-401 delivered using a one-time intracerebral ventricular (ICV) procedure. The company is also developing NGN-101 for the treatment of CLN5 Batten disease.
Company Info
IPO: 2014-03-07
NEUROGENE INC
535 W 24Th Street, 5Th Floor
New York City NEW YORK US
Employees: 107
Phone: 13026587581
NEUROGENE INC / NGNE FAQ
What does NGNE do?
Neurogene, Inc. is a clinical-stage biotechnology company, which engages in the development of product portfolio of genetic medicines for rare neurological diseases. The company is headquartered in New York City, New York and currently employs 107 full-time employees. The company went IPO on 2014-03-07. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is in development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. NGN-401 is being evaluated in female patients with Rett syndrome in a Phase 1/2 open-label, multi-center clinical trial that assesses the safety, tolerability, and efficacy of two doses of NGN-401 delivered using a one-time intracerebral ventricular (ICV) procedure. The company is also developing NGN-101 for the treatment of CLN5 Batten disease.
What is the stock price of NEUROGENE INC today?
The current stock price of NGNE is 19.3 USD. The price decreased by -5.16% in the last trading session.
What is the dividend status of NEUROGENE INC?
NGNE does not pay a dividend.
What is the ChartMill technical and fundamental rating of NGNE stock?
NGNE has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is NEUROGENE INC (NGNE) stock traded?
NGNE stock is listed on the Nasdaq exchange.
When does NEUROGENE INC (NGNE) report earnings?
NEUROGENE INC (NGNE) will report earnings on 2026-05-07, before the market open.
Who owns NEUROGENE INC?
You can find the ownership structure of NEUROGENE INC (NGNE) on the Ownership tab.